Table 3.
Levels of total free (proform/active), active matrix metalloproteinases and tissue inhibitor metalloproteinases in aqueous humor
| Control | POAG | PXS | PXG | |
|---|---|---|---|---|
|
MMP2 |
7.13 ± 1.5 (5.3-10.2) |
23.7 ±10.5 (7.16-44) (p < 0.001)* |
15.8 ± 9.8 (6.1-29.3) (p < 0.001)* |
23.4 ±17.3 (7.1-56.7) (p < 0.001)* |
|
MMP3 |
3.11 ±0.8 (1.6-4.5) |
7.5 ±15.8 (1.3-61) (p = 0.07) |
6.8 ± 11.7 (1.3-44.,2) (p = 0.11) |
9.8 ± 16.8 (1.5-72) (p < 0.001)* |
|
MMP9 |
0.45 ± 0.25 (0.2-0.97) |
0.7 ± 0.6 (0.2-2.1) (p = 0.08) |
0.6 ± 0.33 (0.2-1.3) (p = 0.2) |
0.6 ± 0.35 (0.17-1.5) (p = 0.2) |
|
TIMP1 |
16.3 ± 6.1 (9.3-33.5) |
33.6 ± 19.3 (11–75) (p < 0.001)* |
31.2 ± 14.5 (12–58.5) (p < 0.001)* |
37 ± 15 (15–60.3) (p < 0.001)* |
|
TIMP2 |
3.7 ± 1.1 (2–5.7) |
6.5 ± 3.1 ( 2.1-13.2) (p < 0.001)* |
5.3 ± 2.1 (2.4-8.9) (p < 0.001)* |
6.3 ± 3.1 (2.3-12.2) (p < 0.001)* |
|
TIMP4 |
0.48 ± 0.25 (0.22-0.98) |
0.95 ± 0.49 (0.24-1.76) (p < 0.001)* |
0.48 ± 0.2 (0.13-0.76) (p = 0.93) |
1.28 ± 1.38 (0.4-5.9) (p < 0.001)* |
|
Active MMP2 |
0.21 ± 0.01 (0.2-0.24) |
0.27 ± 0.06 (0.2-0.42) (p < 0.001)* |
0.24 ± 0.03 (0.19-0.3) (p < 0.003)* |
0.25 ± 0.04 (0.19-0.33) (p < 0.001)* |
|
Active MMP3 |
0.29 ± 0.01 (0.26-0.3) |
0.32 ± 0.02 (0.28-0.37) (p < 0.001)* |
0.32 ± 0.01 (0.3-0.35) (p < 0.001)* |
0.32 ± 0.2 (0.29-0.35) (p < 0.001)* |
|
Act/tot. MMP2 |
0.008 ± 0,00086 |
0.006 ±0,00279 (p = 0.03) |
0.005 ±0,00234 (p = 0.004)* |
0.005 ± 0,00299 (p = 0.008)* |
| Act/tot. MMP3 | 0.008 ± 0,00183 | 0.008 ± 0,00061 (p = 0.93) | 0.007 ± 0,0023 (p = 0.1) | 0.008 ± 0,00072 (p = 0.93) |
MMP: Matrix metalloproteinase, TIMP: Tissue inhibitor metalloproteinase, POAG: Primary open angle glaucoma, PXS: Pseudoexfoliation, PXG: Pseudoexfoliation glaucoma. Concentrations (ng/mL) are presented as mean ± SD(range).
p values refer to the Kruskal-Wallis multiple sample test for each study group versus controls. Statistical significance: p < 0.01 after Bonferroni correction.
*: statistically significant.